202 results
6-K
ASND
Ascendis Pharma A/S
2 May 24
Current report (foreign)
4:29pm
, and is expected to last for at least four years. The device enables a single, low-volume injection of less than 0.6 mL for the majority of patients … . Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%); other etiologies include autoimmune disorders, genetic disorders
6-K
EX-99.1
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
in connection with the decision to increase the share capital.
—oo0oo—
The proposals contained in items 1-6 may be adopted by a simple majority of the votes … cast. The proposals contained in item 7 may be adopted by a majority of 2/3 of the votes cast and of the voting share capital represented at the general
6-K
EX-99.2
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
a single, low-volume injection for the majority of patients of less than 0.6 mL and requires a thin, 31-gauge needle that is only 4 millimeters … for the majority of cases (70-80%); other etiologies include autoimmune disorders, genetic disorders such as autosomal dominant hypocalcemia type 1
6-K
EX-1.1
ASND
Ascendis Pharma A/S
10 Apr 24
Current report (foreign)
4:02pm
of which require a qualified majority, the convening notice shall contain a specification of such proposals and their material contents.
The annual … .
The matters discussed at general meetings shall be adopted by a simple majority of votes unless the law or the company’s articles otherwise provide.
In case
6-K
EX-1.1
ASND
Ascendis Pharma A/S
27 Mar 24
Current report (foreign)
4:01pm
majority, the convening notice shall contain a specification of such proposals and their material contents.
The annual general meeting shall be held … meetings shall be adopted by a simple majority of votes unless the law or the company’s articles otherwise provide.
In case of equality of votes
6-K
EX-1.1
xbvff6t8hyz7psxjm5zi
14 Mar 24
Current report (foreign)
4:05pm
6-K
EX-1.1
4pwx7
14 Feb 24
Current report (foreign)
4:07pm
6-K
EX-1.1
23jbun5 4l8m
10 Jan 24
Current report (foreign)
4:02pm
6-K
EX-99.1
t3n pi9qu4uezx
8 Jan 24
Current report (foreign)
6:08am
6-K
EX-1.1
kw2r7 5d0bb6
2 Jan 24
Current report (foreign)
6:08am
6-K
EX-1.1
h1yl8jiapkq
13 Dec 23
Current report (foreign)
4:02pm
6-K
EX-1.1
dqsg8h2cz0y57 a6
15 Nov 23
Current report (foreign)
8:30pm
6-K
pz1ls70
7 Nov 23
Current report (foreign)
4:03pm
6-K
EX-99.1
63i8z qof5ft6j2
7 Nov 23
Ascendis Pharma Reports Third Quarter 2023 Financial Results
4:01pm
6-K
EX-1.1
yf38ntx
11 Oct 23
Current report (foreign)
4:01pm
6-K
EX-1.1
o9uivvh e6
29 Sep 23
Current report (foreign)
4:01pm